Skip to content

Nurix Therapeutics

US · NRIX #2679 by market cap Listed 2020
12.85 -0.75 -5.51%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Valuation each multiple against its own 5-year range

P/B ratio 1.75 Cheap vs history 29th percentile
5-year average 2.91 · #208 of 514 in Biotechnology
P/E ratio 6.37 Expensive vs history 98th percentile
5-year average -4.94 · forward -76.16 · #27 of 77 in Biotechnology
P/S ratio 2.41 Cheap vs history 0th percentile
5-year average 19.57 · forward 5.08 · #61 of 389 in Biotechnology

Vs. peers Biotechnology

Company Market cap P/E (TTM) P/B Div yield
Nurix Therapeutics (NRIX) 1.40B 5.29 1.45 0.00%
Vertex Pharmaceuticals (VRTX) 130.58B 33.14 6.25 0.00%
Regeneron Pharmaceuticals (REGN) 95.24B 20.35 2.84 0.40%
Moderna (MRNA) 78.90B -27.70 11.54 0.00%
argenx SE (ARGX) 58.21B 32.06 6.92 0.00%
BeiGene (ONC) 44.66B 49.74 7.67 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★☆☆ Fair value16.66 Economic moatNone UncertaintyHigh

Trading 29.7% below Morningstar's fair value estimate.

Fair value

Nurix Therapeutics Inc earns a 3-star quantitative star rating, reflecting our opinion that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a 7% discount to our quantitative fair value estimate of $16.66 per share; however, caution is warranted due to this estimate's high uncertainty rating.

The company's valuation metrics bolster our estimated fair value. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. For example, the firm's enterprise value to revenue ratio of 1.0 ranks in the bottom 30% compared with global peers. The prevailing enterprise value/sales ratio is low relative to the long-term earnings power of the business. We believe this is a sign that shares could be undervalued.

The firm's profitability is an additional encouraging factor. Highly profitable companies are often more resilient in recessions and are likely to generate stronger future cash flows for shareholders. The firm's earnings yield of 18.2%, a core component of profitability, falls in the top 10% globally. This suggests that it is generating substantial earnings relative to its share price, which further promotes our favorable price/fair value ratio.

Economic moat

With its quantitative economic moat rating of none, this business is unlikely to consistently outearn its cost of capital without structural protection from competition. However, its financial health score is strong, suggesting that the company should be well positioned to weather tough times.

By Quantitative Equity Report

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

Nurix Therapeutics discussion 0 comments

Add a comment